Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three independent studies suggest a way to thwart a mutated gene that drives tumor growth in 95 percent of people with the disease.
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
Tafinlar and Mekinist approved for a third cancer with specific gene mutation.
People who received the combination treatment had a statistically significant improvement in relapse-free survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.